Latest filing published 02 Jan 2025 for NOVAVAX INC, €42k.
Filing timeline
BuySaleInsider track record
Closed purchases
Based on 5 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- +335.5%Entry US$44.79 · Close at T+365 US$195.04
- +90.7%Entry US$86.20 · Close at T+365 US$164.40
- +138.2%Entry US$38.20 · Close at T+365 US$91.00
- +156.9%Entry US$41.80 · Close at T+365 US$107.40
- +25.4%Entry US$28.40 · Close at T+365 US$35.60
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
James F. Young: trading record in brief
James F. Young (board member) discloses dealings in 2 companies, chiefly Novavax Inc and Medimmune Inc /DE. Over a trading history stretching from 3 February 2006 to 31 December 2024, the count stands at 42 filings.
Market trades split into 5 purchases (€664k) and 20 sales (€5.8M). The net balance comes to €5.1M on the selling side. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Other entries cover 15 option exercises. In 2025 alone, the filings show no purchases and 2 sales.
A typical purchase (the median) is worth €144k. Looking at 5 purchases old enough to measure, the stock rose over the following 90 days in 60% of cases; the median change was +10.9%. Past outcomes like these are no guarantee of what comes next.
Most recently, on 2 January 2025, the filings show an open-market sale worth €42k in Novavax Inc. The clock since the last published purchase (5 June 2020) now reads 2,347 days. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to James F. Young
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 5,400 shares@ US$8.000.7% of flowCommon StockSEC:0001593968-25-000010:1
- 4,600 shares@ US$8.484.2% of flowCommon StockSEC:0001593968-25-000010:0
- 7,500 shares@ US$14.0911.0% of flowCommon StockSEC:0001593968-24-000910:0
- 1,107 shares@ US$14.280.2% of flowCommon StockSEC:0001593968-24-000881:1
- 6,393 shares@ US$13.629.1% of flowCommon StockSEC:0001593968-24-000881:0
- 6,670 shares0Common StockSEC:0001593968-24-000858:0
- 4,600 sharesCommon StockSEC:0001209191-23-036763:0
- 1,400 sharesCommon StockSEC:0001209191-22-038597:0
- 3,255 shares@ US$74.253.6% of flowCommon StockSEC:0001209191-22-022544:1
- 300 shares@ US$75.100.3% of flowCommon StockSEC:0001209191-22-022544:2
- 8,945 shares@ US$73.286766.2% of flowCommon StockSEC:0001209191-22-022544:0
- 3,750 shares@ US$144.167.8% of flowCommon StockSEC:0001209191-22-000955:1
- 3,750 shares@ US$25.609.5% of flowCommon StockSEC:0001209191-22-000955:0
- 10,000 sharesCommon StockSEC:0001209191-21-045561:0
- 7,590 sharesCommon StockSEC:0001209191-21-043695:0
- 10,000 shares@ US$46.007.2% of flowCommon StockSEC:0001209191-21-023076:0
- 4,434 shares@ US$227.4315.7% of flowCommon StockSEC:0001209191-21-023076:1
- 3,120 shares@ US$228.4211.1% of flowCommon StockSEC:0001209191-21-023076:2
- 2,446 shares@ US$229.418.8% of flowCommon StockSEC:0001209191-21-023076:3
- 10,000 shares@ US$27.604.3% of flowCommon StockSEC:0001209191-21-023076:4
- 37,500 shares@ US$3.992.4% of flowCommon StockSEC:0001209191-21-023076:5
- 10,000 sharesCommon StockSEC:0001209191-21-001380:4
- 1,000 shares@ US$50.000.8% of flowCommon StockSEC:0001209191-21-001380:0
- 10,000 shares@ US$51.407.8% of flowCommon StockSEC:0001209191-21-001380:1
- 9,000 shares@ US$112.9815.4% of flowCommon StockSEC:0001209191-21-001380:2
25 of 40 declarations
